Drug Profile
Carbidopa/levodopa controlled-release - Assertio Therapeutics
Alternative Names: DM-1992Latest Information Update: 15 Sep 2021
Price :
$50
*
At a glance
- Originator Depomed
- Developer Assertio Therapeutics
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 15 Sep 2021 Discontinued - Phase-I for Parkinson's disease in Russia (PO) (Assertio Therapeutics pipeline, September 2021)
- 15 Sep 2021 Discontinued - Phase-II for Parkinson's disease in USA (PO) (Assertio Therapeutics pipeline, September 2021)
- 15 Aug 2018 Depomed is now called Assertio Therapeutics